Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingjin Li

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancerAna Oaknin, Bradley J Monk, Ignace Vergote, et al.
Leukemia & Lymphoma|August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapyElżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.
Nucleic Acids Research|October 27, 2022
IAnimal: a cross-species omics knowledgebase for animalsYuhua Fu, Hong Liu, Jingwen Dou, et al.
The New England Journal of Medicine|February 9, 2022
Survival with Cemiplimab in Recurrent Cervical CancerKrishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
The New England Journal of Medicine|June 5, 2018
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancerAna Oaknin, Bradley J Monk, Ignace Vergote, et al.
Leukemia & Lymphoma|August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapyElżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.
Nucleic Acids Research|October 27, 2022
IAnimal: a cross-species omics knowledgebase for animalsYuhua Fu, Hong Liu, Jingwen Dou, et al.
The New England Journal of Medicine|February 9, 2022
Survival with Cemiplimab in Recurrent Cervical CancerKrishnansu S Tewari, Bradley J Monk, Ignace Vergote, et al.
The New England Journal of Medicine|June 5, 2018
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.
Pageof 8